Contribution to characterization of oxidative stress in HIV/AIDS patients

Pharmacological Research

Volumn 47, Issue 3, 2003, Pages 217-224

  Gil, Lizette ^a   Martínez, Gregorio ^b   González, Ivón ^b   Tarinas, Alicia ^a   Álvarez, Alejandro ^a   Giuliani, A ^c   Molina, Randelis ^a   Tápanes, Rolando ^a   Pérez, Jorge ^a   León, Olga Sonia ^b  

^a INSTITUTO DE MEDICINA TROPICAL PEDRO KOURÍ   (Cuba)

^b UNIVERSITY OF HAVANA   (Cuba)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

AIDS; HIV; Oxidative stress; Relative CD4+ T lymphocytes count

Indexed keywords

ANTIOXIDANT; CD38 ANTIGEN; CD4 ANTIGEN; DNA FRAGMENT; FAS ANTIGEN; GLUTATHIONE; GLUTATHIONE PEROXIDASE; HYDROPEROXIDE; MALONALDEHYDE; SUPEROXIDE DISMUTASE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; APOPTOSIS; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CHRONIC INFLAMMATION; CONTROLLED STUDY; ENZYME ACTIVITY; ERYTHROCYTE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LYMPHOCYTE; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; MAJOR CLINICAL STUDY; MALE; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PEROXIDATION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SPECTROPHOTOMETRY; T LYMPHOCYTE;

EID: 12244286787     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-6618(02)00320-1     Document Type: Article

References (50)

1. Repetto M., Reides C., Gomez M.L., Costa M., Griemberg G., Llesuy S. Oxidative stress in blood of HIV patients. Clin. Chim. Acta. 255:1996;107-117.
2. Israel N., Gougerot-Pocidalo M.A. Oxidative stress in human immunodeficiency virus infection. CMLS. 53:1997;864-870.
3. Peterhans E. Reactive oxygen species and nitric oxide in viral diseases. Bio. Trace Elem. Res. 56:1997;107-116.
4. Allard J.P., Aghdassi E., Chau J., Tam C., Kovacs C., Salit I.E.et al. Effects of Vitamins E and C supplementation on oxidative stress and viral load in HIV infected subjects. AIDS. 12:1998;1653-1659.
5. Lee R., Beauparlant P., Elford H., Ponka P., Hiscott J. Selective inhibition of I kappa alpha phosphorylation and HIV-1 LTR-directed gene expression by novel antioxidants compounds. Virology. 234(2):1997;277-290.
6. Greenspan H.C., Aruoma O. Could oxidative stress initiate programmed cell death in HIV infection? A role from plant derived metabolites having synergistic antioxidant activity. Chem. Biol. Interact. 143:1994;145-148.
7. Sharon L.W., Louise M.W., Maureen L.H., Jack P.V., Peter G.W. Oxidative stress and thiol depletion in plasma and peripheral blood lymphocytes from HIV-infected patients: toxicological and pathological implications. AIDS. 11:1997;1689-1697.
8. Kruman I., Nath A., Mattson M. HIV-1 protein Tat induces apoptosis in hipocampal neurons by a mechanism involving caspase activation, calcium overload and oxidative stress. Exp. Neurobiol. 154:1998;276-288.
9. Seve M., Favier A., Osman M., Hernandez D., Vaitaitis G., Flores N.C.et al. The HIV-1 Tat protein increases cell proliferation, alters sensitivity to zinc chelator-induced apoptosis, and change Sp1 DNA binding in HeLa cells. Arch. Biochem. Biophys. 361(2):1999;165-172.
10. Westendorp M.O., Frank R., Ochsenbauer C., Stricker K., Dhein J., Walczak H.et al. Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp 120. Nature. 375:1995;497-500.
11. Frenk S. Enfermedades relacionadas con la acción de radicales libres. Gac Méd Méx. 132(2):1995;199-203.
12. + T cells in vivo by the induction of apoptosis? Immunol. Cell Biol. 77:1999;90-98.
13. + T cells from HIV infected patients increases with disease progression. J. Mol. Med. 73:1995;591-593.
14. McCloskey T.W., Oyaizu N., Kaplan M., Pahwa S. Expression of the Fas antigen in patients infected with human immunodeficiency virus. Cytometry. 22:1995;111-114.
15. Gehri R., Hahn S., Rothen M., Steuerwald M., Nuesch R., Erb P. The Fas receptor in HIV infection: expression on peripheral blood lymphocytes and role in the depletion of T cells. AIDS. 10:1996;9-16.
16. Bohler T., Baumler C., Herr I., Groll A., Kurz M., Debatin K.M. Activation of CD95 system increases with disease progression in human immunodeficiency virus type 1-infected children and adolescent. Pediatr. Infect. Dis. J. 16:1997;754-759.
17. + lymphocyte depletion and human immunodeficiency virus replication. Blood. 89:1997;1357-1363.
18. +, long-term surviving injecting drug users distinguishes those who will progress to AIDS from those who will remain stable. Clin. Exp. Immunol. 122(1):2000;72-78.
19. Jackson D.G., Bellesia E. Isolation of cDNA encoding human CD38 (T10) molecule, a cell surface glycoprotein with an unusual discontinuous pattern of expression during lymphocytes differentiation. J. Immunol. 144:1990;2811-2815.
20. Alessio M., Roggero S., Funaro A., De Monte L.B.P.L., Geuna M., Malavasi F. CD38 molecule: structural and biochemical analysis on human T lymphocytes, thymocytes and plasma cells. J. Immunol. 145:1998;878-884.
21. Aarhus R., Graeff R.M., Dickey D.M., Walseth T.F., Lee H.C. ADP-ribosyl cyclase and CD38 catalyse the synthesis of a calcium-mobilizing metabolite from NADP. J. Biol. Chem. 270:1995;30327-30333.
22. Mahalingam M., Pozniac A., McManus Tj., Vergani D., Peakman M. Cell cycling in HIV infection: analysis of in vivo activated lymphocytes. Clin. Exp. Immnunol. 102:1995;481-486.
23. Meydani S.N., Beharka A.A. Recent developments in vitamin E and the immune response. Nutr. Rev. 56(2):1998;s49-s58.
24. Center for Disease Control. Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Morb Mortal Wkly Rep 1993;14:1-18.
25. Giorgi J.V. Characterization of T lymphocytes subset alterations by flow cytometry in HIV disease. Ann. N. Y. Acad. Sci. 677:1993;126-137.
26. Sedlak J., Lindsay R.H. Estimation of total protein bound and nonprotein sulfhydryl group in tissue with Ellman's reagent. Anal. Biochem. 25:1968;192-205.
27. Premanathan M., Nakashima H., Igarashi R., Mizushima Y., Yamada K. Lecithinized superoxide dismutase: an inhibitor of human immunodeficiency virus replication. AIDS Res. Hum. Retroviruses. 13(4):1997;283-290.
28. Prakash O., Teng S., Ali M., Zhu X., Coleman R., Dabdoub R.A.et al. The HIV-1 Tat protein potentiates Zidovudine-induced cellular toxicity in transgenic mice. Arch. Biochem. Biophys. 343(2):1997;173-180.
29. Erdelmeier I., Gerard D., Yadan J.C., Chaudiere J. Reactions of N-methyl-2-phenyl-indole with malondialdehyde and 4-hydroxialkenals. Mechanistic aspects of the colorimetric assay of lipid peroxidation. Chem. Res. Toxicol. 11(10):1998;1184-1194.
30. Esterbaver H., Cheeseman K.H. Determination of aldehydic lipid peroxidation product: malondialdehyde and 4-hydroxynonenal. Methods Enzymol. 186:1990;407-421.
31. Ozdemirler G., Mehmetcik G., Oztezcan S., Toker G., Sivas A., Uysal M. Peroxidation potential and antioxidant activity of serum in patients with diabetes mellitus and myocard infarction. Metab. Res. 271:1995;194-196.
32. Randox Radicales Libres. Crumlin, UK: Randox Laboratories Ltd.; 1996. p. 1-16.
33. Burton K. Determination of DNA concentration with diphenilamine. Methods Enzymol. 12B:1968;163-167.
34. Muller F., Svardal A.M., Aukrust P., Berge R.K., Ueland P.M., Froland S. Elevated plasma concentration of reduced homocysteine in patients with human immunodeficiency virus infection. Am. J. Clin. Nutr. 63:1996;242-248.
35. + T cells in vivo by the induction of apoptosis? Immunol. Cell Biol. 77:1999;90-98.
36. Piedimonte G., Guetard D., Magnani M., Corsi D., Picerno I., Spataro P.et al. Oxidative protein damage and degradation in lymphocytes from patients infected with human immunodeficiency virus. J. Infect. Dis. 176:1997;655-664.
37. Buhl R., Holroyd K.J., Mastrangeli A., Cantin A.M., Jaffe H.A., Well F.B.et al. Systemic glutathione deficiency in symptom-free HIV-seropositive individuals. Lancet. 2:1989;1294-1298.
38. Sonnerborg A., Carlin G., Akerlund B., Jarstrand C. Increased production of malondialdehyde in patients with HIV infection. Scand. J. Infect. Dis. 20:1988;287-290.
39. Allard J., Aghdassi E., Chau J., Salit I., Walmsley Sh. Oxidative stress and plasma antioxidant micronutrients in humans with HIV infection. Am. J. Clin. Nutr. 67:1998;143-147.
40. Siems W., Pimenov A., Esterbauer H., Grune T. Metabolism of 4-hydroxynonenal, a cytotoxic lipid peroxidation product, in thymocytes as an effective secondary antioxidative defense mechanism. J. Biochem. 123:1998;534-539.
41. Favier A., Sappey C., Leclerc P., Faure P., Micoud M. Antioxidant status and lipid peroxidation in patients infected with HIV. Chem. Biol. Interact. 91:1994;165-180.
42. Zwart L.L., Meerman J.H.N., Commandeur J.N.M., Vermeulen N.P.E. Biomarkers of free radical damage. Applications in experimental animals and in humans. Free Radic. Biol. Med. 26(1/2):1999;202-226.
43. Kinloch R.A., Treherne J.M., Furness L.M., Hafimohamadreza Y. The pharmacology of apoptosis. Trends Pharmacol. Sci. 20:1999;35-42.
44. Gougeon M.L., Oliver R., Garcia S. Demonstration of an engagement process towards cell death by apoptosis in lymphocytes of HIV infected patients. C. R. Acad. Sci. 312:1991;529-537.
45. + T-lymphocytes in asymptomatic HIV infected patients induces the program action of lymphocyte death by apoptosis. C. R. Acad. Sci. 312:1991;599-606.
46. Laurent-Crawford A.G., Krust B., Muller S. The cytopathic effect of HIV is associated with apoptosis. Virology. 185:1991;829-839.
47. Terai C., Kornbluth R.S., Pauza C.D., Richman D.D., Carson D.A. Apoptosis as a mechanism of cell death in culture T lymphoblasts acutely infected with HIV-1. J. Clin. Invest. 87:1991;1710-1715.
48. Prior R.L., Cao G. In vivo total antioxidant capacity: comparison of different analytical methods. Free Radic. Biol. Med. 27(11/12):1999;1173-1181.
49. Fuchs J., Schofer H., Ochesendorf F., Janka S., Milbradt R., Buhl R. Antioxidants and peroxidation products in the blood of HIV-1 infected patients with HIV associated skin diseases. Eur. J. Dermatol. 4:1994;148-153.
50. Romero-Avira D., Roche E. The keys of oxidative stress in acquired immune deficiency syndrome apoptosis. Med. Hyp. 51(2):1998;169-173.